SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[X] Preliminary proxy statement
[ ] Definitive proxy statement
[ ] Definitive additional materials
[ ] Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
LIFERATE SYSTEMS, INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transactions applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11. (Set forth the amount on which the
filing fee is calculated and state how it was determined.)
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
(1) Amount previously paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing party:
(4) Date filed:
<PAGE>
LIFERATE SYSTEMS, INC.
7210 METRO BOULEVARD
EDINA, MINNESOTA 55439
Dear Shareholder:
You are cordially invited to attend a Special Meeting of Shareholders (the
"Special Meeting") of LifeRate Systems, Inc. The Special Meeting will be held on
Wednesday, January 28, 1998, at 9:00 a.m., local time, at Eden Prairie City
Center, 8080 Mitchell Road, Eden Prairie, Minnesota 55344.
We suggest that you carefully read the enclosed Notice of Special Meeting
and Proxy Statement.
We do not plan to make a presentation regarding the Company at the Special
Meeting. However, your vote at the Special Meeting is needed for the Company to
complete the final closing of its current financing. Accordingly, please
complete, sign, date and return the enclosed proxy card in the enclosed envelope
in order to make certain that your shares will be represented at the Special
Meeting.
Very truly yours,
David J. Chinsky
PRESIDENT AND CHIEF EXECUTIVE OFFICER
December 19, 1997
PLEASE SIGN, DATE AND RETURN THE ENCLOSED PROXY PROMPTLY
TO SAVE THE COMPANY THE EXPENSE OF ADDITIONAL SOLICITATION
<PAGE>
LIFERATE SYSTEMS, INC.
7210 METRO BOULEVARD
EDINA, MINNESOTA 55439
------------------
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD JANUARY 28, 1998
------------------
TO THE SHAREHOLDERS OF LIFERATE SYSTEMS, INC.:
A Special Meeting of Shareholders (the "Special Meeting") of LifeRate
Systems, Inc. (the "Company") will be held on Wednesday, January 28, 1998, at
9:00 a.m., local time, at Eden Prairie City Center, 8080 Mitchell Road, Eden
Prairie, Minnesota, 55344, for the following purposes:
1. To consider and act upon a proposal to amend the Company's
Amended and Restated Articles of Incorporation to increase the
number of the Company's authorized shares of common stock from
20,000,000 shares to 75,000,000 shares.
2. To transact such other business as may be properly brought before
the Special Meeting or any adjournment thereof.
Only shareholders of record as shown on the books of the Company at the
close of business on December 12, 1997 will be entitled to vote at the Special
Meeting or any adjournment thereof.
By Order of the Board of Directors
Michel A. LaFond
SECRETARY
December 19, 1997
<PAGE>
LIFERATE SYSTEMS, INC.
7210 METRO BOULEVARD
EDINA, MINNESOTA 55439
PROXY STATEMENT FOR
SPECIAL MEETING OF SHAREHOLDERS
JANUARY 28, 1998
------------------
INTRODUCTION
A Special Meeting of Shareholders (the "Special Meeting") of LifeRate
Systems, Inc. (the "Company") will be held on Wednesday, January 28, 1998, at
9:00 a.m., local time, at Eden Prairie City Center, 8080 Mitchell Road, Eden
Prairie, Minnesota, 55344, or at any adjournment thereof, for the purposes set
forth in the Notice of Meeting.
A proxy card is enclosed for your use. You are solicited on behalf of the
Board of Directors to SIGN, DATE AND RETURN THE PROXY CARD IN THE ACCOMPANYING
ENVELOPE. No postage is required if mailed within the United States. The cost of
soliciting proxies, including the preparation, assembly and mailing of the
proxies and soliciting material, as well as the cost of forwarding such material
to the beneficial owners of the Company's common stock, no par value (the
"Common Stock"), will be borne by the Company. Directors, officers and regular
employees of the Company may, without compensation other than their regular
compensation, solicit proxies by telephone, telegraph or personal conversation.
The Company may reimburse brokerage firms and others for expenses in forwarding
proxy material to the beneficial owners of Common Stock.
Any proxy given pursuant to this solicitation and received in time for the
Special Meeting will be voted in accordance with the instructions given in such
proxy. Any shareholder giving a proxy may revoke it any time prior to its use at
the Special Meeting by giving written notice of such revocation to the Secretary
of the Company. Written notice of revocation may be given prior to the Special
Meeting, or a shareholder may appear at the Special Meeting and give written
notice of revocation prior to use of the proxy.
The Company expects that this Proxy Statement, the Proxy and Notice of
Meeting will first be mailed to shareholders on or about December 19, 1997.
VOTING OF SHARES
Only holders of Common Stock of record at the close of business on December
12, 1997 will be entitled to vote at the Special Meeting. On December 12, 1997,
the Company had 8,480,305 shares of Common Stock outstanding, each such share
entitling the holder thereof to one vote on each matter to be voted on at the
Special Meeting. Holders of shares of Common Stock are not entitled to
cumulative voting rights.
The presence at the Special Meeting, in person or by proxy, of the holders
of a majority of the outstanding shares of Common Stock entitled to vote at the
Special Meeting (4,240,153 shares) is required for a quorum for the transaction
of business. In general, shares of Common Stock represented by a properly signed
and returned proxy card will be counted as shares present at the Special Meeting
for purposes of determining a quorum, without regard to whether the card
reflects abstentions (or is left blank) or reflects a "broker non-vote" on a
matter (i.e., a card returned by a broker on behalf of its beneficial owner
customer that is not voted on a particular matter because voting instructions
have not been received and the broker has no discretionary authority to vote).
<PAGE>
The proposal described in this Proxy Statement requires the approval of a
majority of the shares present and entitled to vote in person or by proxy on the
proposal (and at least a majority of the minimum number of votes necessary for a
quorum to transact business at the meeting). In addition, the Purchase Agreement
described below under the heading "Change in Control" requires that the proposed
amendment to the Company's Amended and Restated Articles of Incorporation be
approved by the affirmative vote of the holders of a majority of shares of
Common Stock held by shareholders other than purchasers under the Purchase
Agreement. Shares represented by a proxy card voted as abstaining on the
proposal will be treated as shares present and entitled to vote that were not
cast in favor of the proposal, and thus will be counted as votes against the
proposal. Shares represented by a proxy card including any broker non-votes on
the proposal will be treated as shares not entitled to vote on the proposal, and
thus will not be counted in determining whether the proposal has been approved.
Shares of Common Stock represented by properly executed proxy cards will be
voted in accordance with the choices specified therein. Proxies that are signed
by shareholders but that lack any voting instructions will be voted in favor of
the proposal described in this Proxy Statement.
PRINCIPAL SHAREHOLDERS AND BENEFICIAL OWNERSHIP OF MANAGEMENT
The following table sets forth information regarding the beneficial
ownership of the Common Stock of the Company as of December 12, 1997, unless
otherwise indicated, by (a) each shareholder who is known by the Company to own
beneficially more than 5% of the outstanding Common Stock, (b) each director,
(c) each "named executive officer" as defined in Item 402(a)(2) of Regulation
S-B of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and
(c) all directors and executive officers of the Company as a group.
SHARES OF COMMON STOCK
BENEFICIALLY OWNED(1)
-------------------------------------
NAME AMOUNT PERCENT OF CLASS(2)
- ---- ------------ -------------------
Special Situations Funds(3) ............. 5,000,000(3) 45.5%
Medtronic Inc. .......................... 700,000(4) 8.2%
David J. Chinsky ........................ 0 0
Daniel A. Pelak ......................... 0(5) 0
Kevin L. Roberg ......................... 0 0
Paul D. Benson .......................... 97,667 1.2%
William W. Chorske ...................... 10,000(6) *
David D. Koentopf ....................... 0 0
David W. Haskin ......................... 138,332(7) 1.6%
Bruce Klein ............................. 0 0
Thomas Niccum ........................... 666 *
All directors and executive
officers as a group (4 persons) ........ 97,667(5) 1.2%
- --------------------
* Less than 1% of the outstanding shares
(1) Unless otherwise noted, all of the shares are held by individuals
possessing sole voting and dispositive power with respect to the shares
shown. Shares not outstanding, but deemed beneficially owned by virtue of
the right of a person or member of a group to acquire them within 60 days,
are treated as outstanding only when determining the amount and percent
owned by such person or group.
(2) Based upon 8,480,305 outstanding shares of Common Stock as of December 1,
1997.
(3) Includes: (i) 1,000,000 shares of Common Stock held by Special Situations
Private Equity Fund, L.P.; (ii) 1,000,000 shares of Common Stock issuable
to Special Situations Private Equity Fund, L.P. pursuant to outstanding
warrants; (iii) 1,100,000 shares of Common Stock held by Special Situations
Fund III, L.P.; (iv) 1,100,000 shares of Common Stock issuable to Special
Situations Fund III, L.P. pursuant to outstanding warrants; (v) 400,000
shares of Common Stock held by Special Situations Cayman Fund, L.P.; and
(vi) 400,000 shares of Common Stock issuable to Special Situations Cayman
Fund, L.P. pursuant to outstanding warrants. Austin W. Marx and David M.
Greenhouse, principals of the investment advisors to the Funds (as
hereinafter defined), are deemed to beneficially own the securities held by
the Funds as reported herein. The address of Special Situations Private
Equity Fund, L.P., Special Situations Fund III, L.P. and Special Situations
Cayman Fund, L.P. (collectively, the "Special Situations Funds" or the
"Funds") is 153 East 53rd Street, 51st Floor, New York, New York 10022.
<PAGE>
(4) Includes 100,000 shares that Medtronic, Inc. has the right to acquire
within 60 days pursuant to the exercise of warrants. The address of
Medtronic, Inc. is 7000 Central Avenue, N.E., Minneapolis, Minnesota 55432.
(5) Does not include any shares beneficially owned by Medtronic, Inc. Mr. Pelak
is an employee of Medtronic and its designee for election to the Board of
Directors.
(6) Includes 10,000 shares that Mr. Chorske has the right to acquire within 60
days pursuant to the exercise of stock options.
(7) Includes 8,332 shares held by two of Mr. Haskin's daughters.
CHANGE IN CONTROL
On November 14, 1997, LifeRate Systems, Inc. (the "Company") entered into a
Securities Purchase Agreement (the "Purchase Agreement") with the Funds and the
other purchasers named in the Purchase Agreement (the Funds and such other
purchasers are collectively referred to herein as the "Purchasers"), pursuant to
which the Company agreed to sell for cash up to 9,000,000 shares (the "Shares")
of common stock, no par value (the "Common Stock") of the Company at prices
ranging from $.50 to $.56 per share and warrants (the "Warrants") to purchase up
to 9,000,000 shares of Common Stock, as well as an additional 104,000 Shares and
Warrants for cancellation of certain indebtedness (the "Financing"). The first
closing under the Purchase Agreement was held on November 14, 1997, at which the
Company issued an aggregate of 2,500,000 Shares at a price of $.50 per share and
issued an aggregate of 2,500,000 Warrants to the Funds for an aggregate purchase
price of $1,250,000 and an aggregate of 104,000 Shares and 104,000 Warrants for
the cancellation of $52,000 of indebtedness (the "First Closing"). The interim
closing called for under the Purchase Agreement was held on November 21, 1997,
at which the Company sold an additional 1,790,000 Shares at a price of $.56 per
share and issued an additional 1,790,000 Warrants to purchasers other than the
Funds for an aggregate purchase price of $1,002,400. The Shares and Warrants
acquired by the Funds in these transactions constitute "beneficial ownership"
(within the meaning of Rule 13d-3 under the Exchange Act) of 45.5% of the
Company's Common Stock as of December 12, 1997, the record date for the Special
Meeting.
The Purchase Agreement also provides that, in the event the Company
fulfills certain conditions by January 15, 1998 (the "Second Closing
Conditions"), the Company will issue up to additional 4,500,000 Shares and
Warrants to purchase 4,500,000 shares of Common Stock at a purchase price of
between $.50 and $.56 per share on or before January 31, 1998 (the "Second
Closing"). The Second Closing Conditions include (a) the approval by the
shareholders of the Company of an amendment to the Company's Articles of
Incorporation to increase the total number of authorized shares of Common Stock
to an aggregate of 75,000,000 at the Special Meeting and (b) the attainment by
the Company no later than January 15, 1998, of the following milestones: (i) the
Company's net revenues derived from the sale of existing or new systems during
the period from October 1, 1997, through January 15, 1998, shall be at least
$200,000; (ii) the Company shall have executed letters of intent and/or sales
contracts, each with a minimum value of $5,000, with at least five new
(excluding current or previous) customers for the sale of any existing or new
systems during the period from October 1, 1997 through January 15, 1998; and
(iii) the Company shall have made generally available for sale a commercially
marketable entry level cardiac cath lab product designed to support the data
requirements of the American College of Cardiology, with a sales price range of
$5,000-$15,000. If the Second Closing Conditions are met, the Funds will be
obligated to purchase 2,500,000 Shares at a price of $.50 per share and
2,500,000 Warrants for an aggregate purchase price of $1,250,000. If all of the
additional 4,500,000 Shares and 4,500,000 Warrants are issued in the Second
Closing, the Funds purchase 2,500,000 of the Shares and Warrants and the Company
does not issue any other shares of Common Stock, the Funds will "beneficially
own" (within the meaning of Rule 13d-3 under the Securities Exchange Act of
1934, as amended) 55.6% of the Company's Common Stock immediately following
the Second Closing.
The net proceeds to be received by the Company if all 9,000,000 of the
Shares and Warrants are sold under the Purchase Agreement, after deducting
commissions of the selling agent and estimated expenses, are estimated to be
approximately $4,298,000. The Company anticipates that the net proceeds from
this offering will be used approximately as follows: Research and Development,
$1,250,000; Customer Support, $625,000; Sales and Marketing, $1,050,000;
Outstanding Accounts Payable, $408,000; Repayment of Indebtedness, $246,400; and
General and Administrative, $718,600. The amounts above
<PAGE>
represent the Company's best estimate of its allocation of the net proceeds of
this offering, based upon the current state of its business operations, its
current plans and current economic and industry conditions. These estimates are
subject to change based upon factors such as the Company's cash needs,
competition, technological developments, market trends and the availability of
alternative financing methods.
As a condition to the First Closing, the Company's Board of Directors was
reduced from ten directors to five directors, and all of the non-employee
directors of the Company, other than Daniel Pelak and Kevin Roberg, resigned
from the Board of Directors. In addition, all of the non-employee directors of
the Company agreed to cancel all options or warrants to purchase shares of
Common Stock held by them (except for certain options to purchase an aggregate
of 236,333 shares held by APF, LLC ("APF") and Dr. Anthony P. Furnary
("Furnary") and options to purchase 10,000 shares, exercisable at $1.00 per
share held by each of William W. Chorske and William Knopf, M.D.). Under the
Purchase Agreement, the Company has also agreed, so long as the Purchasers own
or have the right to acquire at least 20% of the then outstanding shares of
Common Stock, that (a) the Company shall maintain the number of directors who
constitute the Board of Directors at five; (b) so long as the Funds own at least
2.5% of the then outstanding shares of Common Stock, the Company shall maintain
on the Board of Directors one director nominee to be designated by the Funds;
and (c) for a period of three years from the date of the Purchase Agreement, the
Company shall maintain on the Board of Directors one director nominee to be
designated by Miller Johnson & Kuehn Incorporated ("MJK"), which nominee is to
be mutually acceptable to the Company and MJK (the "MJK Director").
The Company agreed to a number of covenants under the Purchase Agreement.
So long as the Purchasers own or have the right to acquire at least 20% of the
outstanding shares of Common Stock, the Company has agreed not to do any of the
following without the consent of the Funds and the MJK Director: (a) sell Common
Stock or any rights or securities convertible into or exercisable or
exchangeable for Common Stock at a purchase, exercise or conversion price, as
the case may be, of less than $1.00 per share of Common Stock for a period of
three years from the date of the Purchase Agreement; (b) issue any securities
senior to the Common Stock; (c) effect any reclassification, capital
reorganization or other change of outstanding shares of capital stock of the
Company; (d) merge, consolidate or enter into any other business combination of
the Company with or into another entity (other than a merger of a wholly owned
subsidiary, in which merger the Company shall be the surviving entity); (e)
sell, lease or otherwise dispose of all or substantially all of its assets; or
(f) liquidate, dissolve or wind-up the Company.
DESCRIPTION OF SECURITIES
At present, the Amended and Restated Articles of Incorporation of the
Company authorize the issuance of 20,000,000 shares of Common Stock, no par
value, and 1,000,000 shares of undesignated preferred stock (the "Undesignated
Stock"). As of December 12, 1997, there were 8,480,305 shares of Common Stock
issued and outstanding and 11,519,695 shares of Common Stock authorized but
unissued and no shares of Undesignated Stock issued and outstanding. Of the
11,519,695 shares of Common Stock that were authorized and unissued, 7,963,355
shares are reserved for issuance pursuant to the Company's 1993 Stock Option
Plan, Employee Stock Purchase Plan, outstanding options, warrants and other
convertible securities of the Company. Accordingly, as of December 12, 1997,
there were 3,556,340 shares of Common Stock available for issuance or sale by
the Company other than those issuable as described above. The Company has not
declared or paid any cash dividends on its Common Stock since its inception and
does not intend to pay any dividends for the foreseeable future.
COMMON STOCK
All outstanding shares of Common Stock are fully paid and nonassessable.
Each share of the outstanding Common Stock is entitled to participate equally in
dividends as and when declared by the Board of Directors and is entitled to
participate equally in any distribution of net assets made to the shareholders
upon liquidation of the Company. There are no redemption, sinking fund,
conversion or preemptive rights with respect to the shares of Common Stock,
except for the contractual preemptive
<PAGE>
right held by Medtronic, Inc. All shares of Common Stock have equal rights and
preferences. The holders of Common Stock are entitled to one vote for each share
held of record on all matters voted upon by shareholders and may not cumulate
votes for the election of directors. Accordingly, the owners of a majority of
the shares of Common stock outstanding may elect all of the directors of the
Company if they choose to do so, and the owners of the balance of such shares
would not be able to elect any directors.
UNDESIGNATED STOCK
Under applicable Minnesota law, no action by the Company's shareholders is
necessary, and only action of the Board of Directors is required, to authorize
the issuance of any Undesignated Stock. The Board of Directors is empowered to
establish, and to designate the name of, each class or series of the shares of
Undesignated Stock and to set the terms of such shares (including terms with
respect to redemption, sinking fund, dividend, liquidation, preemptive,
conversion and voting rights and preferences). The Board of Directors can issue
shares of such class or series to, among other individuals, the holders of
another class or series of preferred stock or to the holders of Common Stock.
Accordingly, the Board of Directors, without shareholder approval, can issue
preferred stock with voting or conversion rights which could adversely affect
the voting power of the holders of the Common Stock. The Undesignated Stock may
have the effect of discouraging an attempt, through acquisition of a substantial
number of shares of Common Stock, to acquire control of the Company with a view
to effecting a merger, sale or exchange of assets or a similar transaction. For
example, the Board of Directors could issue such shares as a dividend to holders
of Common Stock or place such shares privately with purchasers who may side with
the Board of Directors in opposing a takeover bid.
PROPOSAL TO AMEND THE ARTICLES OF INCORPORATION
TO INCREASE THE AUTHORIZED COMMON STOCK OF THE COMPANY
PROPOSAL 1
INTRODUCTION
At present, the Amended and Restated Articles of Incorporation of the
Company authorize the issuance of 20,000,000 shares of Common Stock, no par
value. As of December 12, 1997, 8,480,305 shares of the Company's authorized
shares of Common Stock were issued and outstanding and 11,519,695 shares were
authorized but unissued. Of the 11,519,695 shares of Common Stock that were
authorized and unissued, 7,963,355 shares are reserved for issuance pursuant to
the Company's 1993 Stock Option Plan, Employee Stock Purchase Plan, outstanding
options, warrants and other convertible securities of the Company. Accordingly,
as of December 12, 1997, there were 3,556,340 shares of Common Stock available
for issuance or sale by the Company other than those issuable as described
above.
The Board of Directors has unanimously proposed that the Company's Amended
and Restated Articles of Incorporation be amended to increase the authorized
number of shares of Common Stock from 20,000,000 to 75,000,000 and that this
amendment should be presented to the Company's shareholders at the Special
Meeting. The Company anticipates that up to 4,500,000 Shares and 4,500,000
Warrants will be issued in connection with the Purchase Agreement at the Second
Closing. Accordingly, if this amendment is approved by the shareholders,
49,556,340 shares of Common Stock will be authorized for issuance and unreserved
immediately after the Second Closing, assuming all 4,500,000 Shares and
4,500,000 Warrants are issued in the Second Closing. The Company does not
currently have a sufficient number of authorized and unreserved shares of Common
Stock to complete the Second Closing, and this amendment must be approved in
order to complete the Second Closing. The number of shares of Undesignated Stock
authorized under the Amended and Restated Articles of Incorporation, which is
currently 1,000,000 shares, will not be changed by this amendment. At the
Special Meeting, the shareholders of the Company are being asked to approve this
amendment.
PURPOSE AND EFFECTS OF THE PROPOSED AMENDMENT
The purpose of adopting the proposed amendment is to enable the Company to
consummate the transactions contemplated by the Purchase Agreement and to
complete the Second Closing. In addition,
<PAGE>
the Board of Directors believes that it is necessary and desirable to increase
the number of shares of Common Stock the Company is authorized to issue to give
the Board of Directors additional flexibility to declare stock splits or
dividends, adopt additional future employee benefit plans, make acquisitions
through the use of stock, increase the number of shares in the market, enable
the Board of Directors to reserve additional shares for issuance under any
options, warrants or convertible securities which may be issued and raise equity
capital. The Board of Directors has no immediate plans, understandings or
agreements or commitments to issue additional shares of Common Stock for any of
these purposes, except in connection with the Purchase Agreement discussed above
and except as permitted or required by outstanding options, warrants,
convertible securities and additional options which may be granted from time to
time under the Company's 1993 Stock Option Plan. The flexibility inherent in
having the authority to issue shares of Common Stock will, in the opinion of the
Board of Directors, be advantageous to the Company in any negotiations involving
the issuance of such stock. If the shareholders fail to approve the proposed
amendment the Company will not be able to complete the Second Closing under the
Purchase Agreement, which would materially and adversely affect the Company's
ability to finance continuing operations. In addition, if the authorization of
additional shares of Common Stock (beyond the number of shares needed to
complete the Second Closing) are deferred until a specific need existed, the
time and expense required in connection with obtaining the necessary shareholder
action for each proposed issuance could deprive the Company of flexibility that
the Board of Directors believes will result in the most efficient use of such
shares. If this proposed amendment is adopted, no additional action or
authorization by the Company's shareholders will be necessary prior to the
issuance of such additional shares, unless required by applicable law or
regulation, or unless deemed desirable or advisable by the Board of Directors.
If adopted, the proposal will not, by itself, have any effect on the rights
of holders of presently issued and outstanding shares of Common Stock. Under the
Company's Amended and Restated Articles of Incorporation, the shareholders of
the Company do not have preemptive rights with respect to the Common Stock.
Thus, should the Board of Directors elect to issue additional shares of Common
Stock, existing shareholders would not have any preferential rights to purchase
such additional shares of Common Stock.
Although the Board of Directors is proposing this amendment to the
Company's Amended and Restated Articles of Incorporation for the reasons stated
above, the amendment could, under certain circumstances, discourage or make more
difficult an attempt by a person or organization to gain control of the Company
by tender offer or proxy contest, or to consummate a merger or consolidation
with the Company after acquiring control, and to remove incumbent management,
even if such transactions were favorable to the shareholders of the Company.
Issuance of shares of Common Stock in a private placement to a person
sympathetic to management and opposed to any attempt to gain control of the
Company could make a change in control of the Company more difficult.
Accordingly, this proposal to amend the Company's Amended and Restated Articles
of Incorporation may be deemed (under certain circumstances which may or may not
occur) to be an anti-takeover measure. However, the proposal is not being
presented as an anti-takeover measure.
PROPOSED RESOLUTION
A resolution in substantially the following form will be submitted to the
shareholders at the Special Meeting:
RESOLVED, that the second sentence of Article III of the Company's Amended
and Restated Articles of Incorporation is amended in its entirety to read
as follows:
"The total number of shares of all classes of capital stock which the
Corporation shall be authorized to issue is 76,000,000, consisting of
75,000,000 shares of common stock and 1,000,0000 shares of preferred
stock."
RESOLVED FURTHER, that the appropriate officers of the Company are
authorized and directed to make, execute, acknowledge and file such
certificates and documents as may be required by law with respect to the
foregoing resolutions.
<PAGE>
BOARD OF DIRECTORS' RECOMMENDATION
The Board of Directors recommends a vote FOR approval of this amendment.
The affirmative vote of the holders of a majority of shares of Common Stock of
the Company present in person or by proxy at the Special Meeting, assuming a
quorum is present, is necessary for approval. In addition, the Purchase
Agreement requires that this amendment be approved by the affirmative vote of
the holders of a majority of shares of Common Stock held by shareholders other
than purchasers under the Purchase Agreement. Unless a contrary choice is
specified, proxies solicited by the Board of Directors will be voted FOR the
approval of this amendment.
INTERESTS OF CERTAIN PERSONS
If the proposed amendment to the Company's Amended and Restated Articles of
Incorporation is approved and the Company completes the Second Closing, the
Funds will acquire an additional 2,500,000 shares of Common Stock and 2,500,000
warrants pursuant to the Purchase Agreement.
PROPOSALS FOR THE 1998 ANNUAL MEETING
It is anticipated that the next shareholders' meeting will be held in May
1998. Shareholder proposals intended to be presented in the proxy materials
relating to the 1998 Annual Meeting of Shareholders must be received by the
Company on or before December 25, 1997.
OTHER BUSINESS
The Company knows of no business that will be presented for consideration
at the Special Meeting other than that described in this Proxy Statement. As to
other business, if any, that may properly come before the Special Meeting, it is
intended that proxies solicited by the Board will be voted in accordance with
the judgment of the person or persons voting the proxies.
<PAGE>
LIFERATE SYSTEMS, INC. PROXY
7210 METRO BOULEVARD
EDINA, MINNESOTA 55439
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF
LIFERATE SYSTEMS, INC.
The undersigned hereby appoints David J. Chinsky and Kenneth G. Tarr, and each
of them, as Proxies, each with the power to appoint his substitute, and hereby
authorizes each of them to represent and to vote, as designated below, all the
shares of common stock of LifeRate Systems, Inc. held of record by the
undersigned on December 12, 1997, at the Special Meeting of Shareholders to be
held on January 28, 1998 or any adjournment thereof.
1. PROPOSAL TO AMEND THE COMPANY'S ARTICLES OF INCORPORATION TO INCREASE THE
NUMBER OF AUTHORIZED SHARES OF COMMON STOCK.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
2. IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER
BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL 1 ABOVE.
(PLEASE SIGN ON REVERSE SIDE)
<PAGE>
(CONTINUED FROM OTHER SIDE)
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN
BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE
VOTED FOR PROPOSAL 1 ABOVE. Please sign exactly as name appears below. When
shares are held by joint tenants, both should sign. When signing as attorney,
executor, administrator, trustee or guardian, please give full title as such. If
a corporation, please sign in full corporate name by President or other
authorized officer. If a partnership, please sign in partnership name by
authorized person.
Date:_____________________________, 1997
________________________________________
Signature
________________________________________
Signature if held jointly
PLEASE MARK, SIGN, DATE AND RETURN THE
PROXY CARD PROMPTLY USING THE ENCLOSED
ENVELOPE, WHICH REQUIRES NO POSTAGE IF
MAILED IN THE UNITED STATES.
